Strides Pharma Science Limited has informed the Exchange regarding a press release dated September 14, 2023, titled "Strides receives tentative USFDA approval for Dolutegravir tablets".
Press Release Sep 14 2023
Filed with NSE ·
6ix hasn’t read this filing yet.
Strides Pharma Science Ltd on 6ix
Earlier from Strides Pharma Science
- Press Release Sep 09 2023
- Press Release Aug 30 2023
- Press Release Aug 02 2023
- Intimation of Board Meeting scheduled on August 2, 2023
- Press Release Jul 04 2023
Later from Strides Pharma Science
- Intimation of Board Meeting scheduled on Sept 25, 2023
- Press Release Sep 23 2023
- Press Release (Revised) Oct 03 2023
- Press Release Oct 04 2023
- Press Release Oct 30 2023
Follow Strides Pharma Science into a list and get an email when it puts out news.
Follow Strides Pharma Science